ClinicalTrials.gg
Not yet recruitingNCT07856654SUSIUpdated Oct 2, 2026

Suzetrigine Following Urogynecologic Surgery: Investigation of Postoperative Pain Management

A Phase 4 interventional study of Suzetrigine and Placebo in Pelvic Organ Prolapse (POP), Postoperative Pain and Urogynecology, sponsored by Aditi Talkad. Not yet recruiting at 1 site in United States. Open to female participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Aditi Talkad · Phase 4, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Pelvic Organ Prolapse with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Pelvic Organ Prolapse · United States.

Planned enrollment
102nd of 133
48 · median 78
Started
2026
with 4 others
Phase 4
25 of 195
2 open now
Primary completion
2027-12
later than 19 of 22 live
Registered
195th of 195
by date

Among the 195 studies in Pelvic Organ Prolapse with a site in United States, this one is the 102nd largest by planned enrollment of the 133 interventional ones that give a count, is one of 5 that started in 2026, is one of 25 in phase 4, reaches primary completion later than 19 of the 22 other live ones, and was the 195th registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

12 of the 195 studies in Pelvic Organ Prolapse with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 40 Years to 80 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Pelvic Organ Prolapse with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether suzetrigine, when added to standardized multimodal postoperative analgesia improves pain control and reduces opioid consumption after apical suspension surgery for pelvic organ prolapse.

Researchers will compare suzetrigine to a placebo (a look-alike substance that contains no drug) to evaluate this outcome.

The main questions it aims to answer are:

  • Does suzetrigine reduce postoperative pain scores compared to placebo?
  • Does suzetrigine reduce the need for opioid rescue medication after surgery?

Researchers will compare participants receiving suzetrigine to participants receiving placebo, both on top of standard postoperative pain management, to see if suzetrigine lowers pain scores and opioid consumption after apical suspension surgery.

Read the detailed description

Suzetrigine is a first-in-class, selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. It was approved by the FDA in 2025 as a non-opioid alternative for moderate-to-severe pain following Phase 3 studies in abdominoplasty and bunionectomy. This single-center, randomized, double-blinded, placebo-controlled trial evaluates whether a suzetrigine-based postoperative analgesic regimen reduces opioid consumption and improves pain control compared with standard opioid-inclusive care following apical suspension surgery for pelvic organ prolapse. The study will enroll participants in a 1:1 ratio and assess pain, opioid consumption, adverse events, and patient-reported recovery over 7 days postoperatively.

03

Conditions studied

  • Pelvic Organ Prolapse (POP)
  • Postoperative Pain
  • Urogynecology

Keywords

  • postoperative pain
  • suzetrigine
  • pelvic organ prolapse
  • urogynecology
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ≥ 40 years and ≤ 80
  • >=18.0 and \<= 40.0
  • Can read and speak English or Spanish
  • Undergoing major urogynecologic surgery, defined as having at least one of the following:

    • Robotic-assisted laparoscopic sacrocolpopexy
    • Uterosacral ligament suspension (laparoscopic or vaginal approach)
    • Uterosacral hysteropexy
    • Sacrospinous hysteropexy
    • Sacrospinous ligament fixation
    • Conversion to laparotomy during primary surgery for prolapse repair

Exclusion criteria

Exclusion Criteria:

    • Current narcotic use defined as daily use for more than 7 consecutive days in the 3 months prior to surgery, or current treatment for opioid use disorder.

      • Any opioid use within 30 days prior to the scheduled procedure date.
      • Significant hepatic disease, defined as or ALT >3 times the or class B or C.
      • Diagnosis of chronic pain syndrome or fibromyalgia
      • Inability to provide written
      • History of significant respiratory, cardiovascular, metabolic, neurologic, or psychiatric disease as deemed by study team
      • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) within the last 2 years or (QTcF >450 ms) or pacemaker/ICD
      • Severe kidney disease define as Estimated (eGFR) of ≤ 30ml/min
      • Inability to receive or respond to text messages via mobile phone
      • Receives transversus abdominis plane (TAP) block
      • Allergy to any of the study medications
      • Use of moderate or strong inducers or inhibitors, including prescription medications, over-the-counter medications, and herbal supplements known to significantly affect CYP3A metabolism (e.g., ketoconazole, clarithromycin, rifampin, carbamazepine, phenytoin, ritonavir, and St. John's Wort).
      • Pregnant or breastfeeding or planning to become pregnant within 30 days following last dose of study drug
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants will receive suzetrigine 100 mg (2 tablets) as a loading dose on the evening of surgery, followed by 50 mg every 12 hours for 7 days, in addition to standard multimodal analgesia. Standard analgesia consists of ibuprofen 600 mg every 6 hours and acetaminophen 650 mg every 6 hours, scheduled for the first 48 hours postoperatively, after which patients may transition to as-needed dosing of both. An opioid prescription will be sent if triggered by previously set score and based on the patient's reported pain score.

    Drug: Suzetrigine

  • Experimental
    Control Group

    Participants will receive matching placebo as a loading dose (2 tablets) on the evening of surgery, followed by 1 tablet every 12 hours for 7 days, in addition to standard multimodal analgesia. Standard analgesia consists of ibuprofen 600 mg every 6 hours and acetaminophen 650 mg every 6 hours, scheduled for the first 48 hours postoperatively, after which patients may transition to as-needed dosing of both. An opioid prescription will be sent if triggered by the patient's reported pain score.

    Drug: Placebo

Interventions

  • Suzetrigine (JOURNAVX), an oral, first-in-class, selective NaV1.8 inhibitor, administered as a 100 mg (2-tablet) loading dose on the evening of surgery, followed by 50 mg every 12 hours for 7 days, in addition to standard postoperative multimodal analgesia (scheduled ibuprofen and acetaminophen for the first 48 hours). Suzetrigine is FDA-approved for moderate-to-severe acute pain and provides peripheral analgesia without opioid-related CNS effects.

    Also known as: Experimental Group

  • DrugPlacebo

    Placebo, matched in appearance to suzetrigine and formulated by the site's investigational pharmacy, administered as a 2-tablet loading dose on the evening of surgery, followed by 1 tablet every 12 hours for 7 days, in addition to standard postoperative multimodal analgesia (scheduled ibuprofen and acetaminophen for the first 48 hours).

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Score

    Postoperative pain will be assessed using the Visual Analog Scale with change from baseline compared between patients receiving adjunctive suzetrigine versus standard multimodal postoperative pain management alone. This will assessed on a daily survey postoperatively.

    Time frame: Baseline (preoperative) to 7 days postoperatively

Secondary outcomes

  1. Cumulative Postoperative Opioid Consumption

    Total opioid consumption, measured in morphine milligram equivalents (MME), will be assessed via daily patient-reported surveys collected through postoperative day 7 and compared between patients receiving suzetrigine versus placebo groups.

    Time frame: 7 days postoperatively

  2. Patient-Reported Outcomes and Satisfaction With Postoperative Recovery

    Patient-perceived control over pain management will be assessed using selected items from the American Pain Society Patient Outcome Questionnaire-Revised (APS-POQ-R), adapted for outpatient use following discharge.

    Time frame: 7 days postoperatively

  3. Treatment Tolerability

    Treatment tolerability, including incidence of side effects, will be assessed via daily patient-reported surveys collected through postoperative day 7 and compared between patients receiving suzetrigine versus placebo.

    Time frame: 7 days postoperatively

07

Study locations

1 site
08

References and documents

Publications

  • Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870. PubMed 37530822 ↗
  • Myles PS, Myles DB, Galagher W, Boyd D, Chew C, MacDonald N, Dennis A. Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. Br J Anaesth. 2017 Mar 1;118(3):424-429. doi: 10.1093/bja/aew466. PubMed 28186223 ↗
  • Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PubMed 40117446 ↗
  • Nilsson W, Narwold E, Turner L, Shepherd J. Comparing Post-Operative Pain Outcomes in Pelvic Organ Prolapse Surgery With and Without a Hysterectomy. Int Urogynecol J. 2025 Aug;36(8):1649-1654. doi: 10.1007/s00192-025-06162-6. Epub 2025 May 10. PubMed 40347243 ↗
  • Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1. PubMed 36327391 ↗
  • By the 2023 American Geriatrics Society Beers Criteria(R) Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4. PubMed 37139824 ↗
  • Willis-Gray MG, Young JC, Pate V, Jonsson Funk M, Wu JM. Perioperative opioid prescriptions associated with stress incontinence and pelvic organ prolapse surgery. Am J Obstet Gynecol. 2020 Dec;223(6):894.e1-894.e9. doi: 10.1016/j.ajog.2020.07.004. Epub 2020 Jul 9. PubMed 32653459 ↗
  • Agrawal P, Choi U, Liao B, Kohn TP, Kohn J, Dumas K, Clifton M. Perioperative Pain Management With Opioid Analgesics in Colpopexy Increases Risk of New Persistent Opioid Usage. Urogynecology (Phila). 2023 Feb 1;29(2):183-190. doi: 10.1097/SPV.0000000000001305. PubMed 36735432 ↗
  • Swenson CW, Kamdar NS, Seiler K, Morgan DM, Lin P, As-Sanie S. Definition development and prevalence of new persistent opioid use following hysterectomy. Am J Obstet Gynecol. 2018 Nov;219(5):486.e1-486.e7. doi: 10.1016/j.ajog.2018.06.010. Epub 2018 Jun 19. PubMed 29928864 ↗
  • AlAshqar A, Ishiwata R, Moss C, Andersen KM, Yanek L, Bicket MC, Alexander GC, Borahay MA. Predictors of new persistent opioid use after benign hysterectomy in the United States. Am J Obstet Gynecol. 2022 Jul;227(1):68.e1-68.e24. doi: 10.1016/j.ajog.2022.02.030. Epub 2022 Mar 3. PubMed 35248573 ↗
  • Wright JD, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL. Use and Misuse of Opioids After Gynecologic Surgical Procedures. Obstet Gynecol. 2019 Aug;134(2):250-260. doi: 10.1097/AOG.0000000000003358. PubMed 31306333 ↗
  • Selle JM, Strozza DM, Branda ME, Gebhart JB, Trabuco EC, Occhino JA, Linder BJ, El Nashar SA, Madsen AM. A bundle of opioid-sparing strategies to eliminate routine opioid prescribing in a urogynecology practice. Am J Obstet Gynecol. 2024 Aug;231(2):278.e1-278.e17. doi: 10.1016/j.ajog.2024.05.043. Epub 2024 May 25. PubMed 38801934 ↗
  • Reagan KML, O'Sullivan DM, Gannon R, Steinberg AC. Decreasing postoperative narcotics in reconstructive pelvic surgery: a randomized controlled trial. Am J Obstet Gynecol. 2017 Sep;217(3):325.e1-325.e10. doi: 10.1016/j.ajog.2017.05.041. Epub 2017 May 25. PubMed 28551445 ↗
  • Yuan AS, Propst KA, Ross JH, Wallace SL, Paraiso MFR, Park AJ, Chapman GC, Ferrando CA. Restrictive opioid prescribing after surgery for prolapse and incontinence: a randomized, noninferiority trial. Am J Obstet Gynecol. 2024 Mar;230(3):340.e1-340.e13. doi: 10.1016/j.ajog.2023.10.027. Epub 2023 Oct 18. PubMed 37863158 ↗
  • Petrikovets A, Sheyn D, Sun HH, Chapman GC, Mahajan ST, Pollard RR, El-Nashar SA, Hijaz AK, Mangel J. Multimodal opioid-sparing postoperative pain regimen compared with the standard postoperative pain regimen in vaginal pelvic reconstructive surgery: a multicenter randomized controlled trial. Am J Obstet Gynecol. 2019 Nov;221(5):511.e1-511.e10. doi: 10.1016/j.ajog.2019.06.002. Epub 2019 Jun 12. PubMed 31201808 ↗
  • Ramaseshan AS, O'Sullivan DM, Steinberg AC, Tunitsky-Bitton E. A comprehensive model for pain management in patients undergoing pelvic reconstructive surgery: a prospective clinical practice study. Am J Obstet Gynecol. 2020 Aug;223(2):262.e1-262.e8. doi: 10.1016/j.ajog.2020.05.019. Epub 2020 May 13. PubMed 32413429 ↗
  • Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. doi: 10.1016/j.jpain.2007.09.005. Epub 2007 Dec 11. PubMed 18055266 ↗
  • Linder BJ, Occhino JA, Wiest SR, Klingele CJ, Trabuco EC, Gebhart JB. Assessing the impact of procedure-specific opioid prescribing recommendations on opioid stewardship following pelvic organ prolapse surgery. Am J Obstet Gynecol. 2019 Nov;221(5):515.e1-515.e8. doi: 10.1016/j.ajog.2019.06.023. Epub 2019 Jun 18. PubMed 31226293 ↗
  • ACOG Committee Opinion No. 750: Perioperative Pathways: Enhanced Recovery After Surgery. Obstet Gynecol. 2018 Sep;132(3):e120-e130. doi: 10.1097/AOG.0000000000002818. PubMed 30134426 ↗
  • Rogers RG, Leeman LL. Postpartum genitourinary changes. Urol Clin North Am. 2007 Feb;34(1):13-21. doi: 10.1016/j.ucl.2006.10.005. PubMed 17145356 ↗

Individual participant data

Plan to share: Undecided — A decision on individual participant data (IPD) sharing has not yet been finalized. This will be determined prior to study completion, pending institutional data-sharing policy review and consideration of participant privacy given the study's relatively small, single-site sample size.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2027
CompletionEst.
May 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856654
Lead sponsor
Aditi Talkad
Responsible party
Aditi Talkad (Co Investigator, University of Texas at Austin) — Sponsor-investigator
First posted
Oct 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Aditi Talkad MD
Contact
aditi.talkad@ascension.org
404-434-3889
Amanda White, MD
principal investigator · University of Texas at Austin Dell Medical School, Department of Women's Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion